The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of panitumumab with FOLFOX or FOLFIRI as first-line chemotherapy for KRAS-wild type metastatic colorectal cancer: The PaFF-J study.
 
Eiji Shinozaki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Megumi Ishiguro
Honoraria - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical; Yakult Honsha
 
Eiji Nakatani
No Relationships to Disclose
 
Tatsuro Yamaguchi
No Relationships to Disclose
 
Masato Nakamura
Honoraria - Takeda; Yakult Honsha
 
Yuji Miyamoto
No Relationships to Disclose
 
Hitoshi Ojima
No Relationships to Disclose
 
Yoshitaka Honma
Speakers' Bureau - Nihonkayaku; Novartis; Taiho Pharmaceutical
 
Masahiro Gotoh
No Relationships to Disclose
 
Toshiaki Ishikawa
Honoraria - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda
 
Keiichi Takahashi
Honoraria - Chugai Pharma; Ethicon; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yasuhiro Shimada
Honoraria - Chugai Pharma; Lilly Japan; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Lilly Japan; Merck Serono; Taiho Pharmaceutical
 
Kazuhiro Yoshida
Honoraria - Chugai Pharma; Daiichi Sankyo; EA Pharma; Lilly Japan; Merck Serono; Novartis; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); EA Pharma (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
Travel, Accommodations, Expenses - Chugai Pharma; Daiichi Sankyo; EA Pharma; Lilly Japan; Merck Serono; Novartis; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Nobuyuki Mizunuma
No Relationships to Disclose
 
Kei Muro
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Yoshito Komatsu
Honoraria - Bayer; Novartis; Pfizer
Research Funding - Bayer; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Kensei Yamaguchi
Speakers' Bureau - Chugai Pharma; Lilly Japan; Merck Serono; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Hiroshi Nakano
No Relationships to Disclose
 
Junki Koike
No Relationships to Disclose
 
Kenichi Sugihara
Honoraria - Bayer; Chugai Pharma; Merck Serono; Novartis; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer
Research Funding - Chugai Pharma; Taiho Pharmaceutical